Avacta News Feed

Avacta Group Plc making 'excellent progress' on lead programmes

Alastair Smith, chief executive of Avacta Group Plc ( LON:AVCT ), tells Proactive Investors their lead PD-L1 programme remains on track to deliver key pre-clinical milestones this year. Smith says they're also making “excellent progress” with a second immuno-oncology research project, a LAG3 blockade, which can be combined with...

Avacta enters significant partnership with OncoSec Medical

Alastair smith, chief executive of Avacta Group Plc ’s ( LON:AVCT ), tells Proactive that interest in their Affimer technology continues to grow following the announcement of another collaboration agreement - this time with OncoSec Medical Inc (NASDAQ:ONCS). OncoSec has developed a gene delivery technology called ImmunoPulse...

Avacta boss praises “strong” progress made in first half

“We have continued to grow the number and extent of the data packages demonstrating the power of the Affimer technology in therapeutic and non-therapeutic applications which build the commercial case and de-risk the technology for third parties”

Avacta agrees licensing deal with antibody drug conjugates specialist Glythera

"I am delighted with the reciprocal arrangements that we have put in place with Glythera allowing both companies to develop Affimer-Permalink drug conjugates," said Avacta's CEO, Alastair Smith

Avacta partner to present data on breakthrough technology at Barcelona conference

Avacta’s chief executive, Dr Alastair Smith, said the presentation provided “strong, independent validation of the technical performance of Affimer reagents and is important to our commercialisation of the technology”

Interest in Affimer technology at record levels, which bodes well for Avacta

Affimers are small, engineered proteins, some of which are of human origin and some plant-derived. They are capable of binding specific molecular targets, in a similar way to antibodies.